Technical Analysis for SHPGF - Shire Plc Ord

Grade Last Price % Change Price Change
grade A 63.0 5.00% 3.0000
SHPGF closed up 5.0 percent on Monday, March 4, 2019, on 7 percent of normal volume. The bulls were able to push the stock to a new 52-week high. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up
Historical SHPGF trend table...

Date Alert Name Type % Chg
New 52 Week Closing High Bullish 0.00%
Narrow Range Bar Range Contraction 0.00%
New 52 Week High Strength 0.00%
Stochastic Reached Overbought Strength 0.00%
Gapped Up Strength 0.00%
Overbought Stochastic Strength 0.00%
Narrow Range Bar Range Contraction 5.00%
Gapped Down Weakness 5.00%
Narrow Range Bar Range Contraction 3.28%
Gapped Up Strength 3.28%
Older signals for SHPGF ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Its marketed products include ADVATE, ADYNOVATE/ADYNOVI, and OBIZUR for the treatment of hemophilia A; RIXUBIS to treat hemophilia B; VONVENDI for the treatment of von willebrand disease; FEIBA to treat hemophilia A and B patients with inhibitors; ELAPRASE to treat hunter syndrome; REPLAGAL for fabry disease; and VPRIV to treat type 1 Gaucher disease. The company's marketed products also comprise VYVANSE/VENVANSE/ELVANSE/TYVENSE/VUXEN/ADUVANZ for the treatment of attention deficit/hyperactivity disorder (ADHD) and binge eating disorder; ADDERALL XR and MYDAYIS to treat ADHD; GAMMAGARD LIQUID/KIOVIG, GAMMAGARD S/D, HYQVIA, and CUVITRU for the treatment of primary immunodeficiency; and FLEXBUMIN to treat hypovolemia and hypoalbuminemia. In addition, its marketed products consists of CINRYZE and FIRAZYR for the treatment of hereditary angioedema; FOSRENOL to treat hyperphosphatemia; LIALDA/MEZAVANT and PENTASA for ulcerative colitis; GATTEX/REVESTIVE for the treatment of short bowel syndrome; NATPARA for the control of hypocalcemia in patients with hypoparathyroidism; ONCASPAR to treat acute lymphoblastic leukemia; ONYVIDE for metastatic adenocarcinoma of the pancreas; and XIIDRA for the treatment of dry eye disease. The company markets its products through wholesalers, distributors, and pharmacies. The company was founded in 1986 and is headquartered in Dublin, Ireland. Shire plc is a subsidiary of Takeda Pharmaceutical Company Limited.
Medicine Biotechnology RTT Drugs Psychoactive Drugs Neuroscience Rare Diseases Ulcerative Colitis Acute Lymphoblastic Leukemia Amphetamine Takeda Pharmaceutical Company Hereditary Angioedema Gaucher Disease Hemophilia A Short Bowel Syndrome Treatment Of Short Bowel Syndrome Adhd Dry Eye Disease Fabry Disease Genetic Diseases Haemophilia B Hyperphosphatemia Treatment Of Hemophilia Hemophilia B Hypoparathyroidism Metastatic Adenocarcinoma

Is SHPGF a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Recent News


Indicator Value
52 Week High 63.0
52 Week Low 40.99
Average Volume 2,962
200-Day Moving Average 53.7313
50-Day Moving Average 58.2496
20-Day Moving Average 59.5210
10-Day Moving Average 60.9040
Average True Range 1.3045
ADX 19.32
+DI 44.0450
-DI 21.2015
Chandelier Exit (Long, 3 ATRs ) 59.0865
Chandelier Exit (Short, 3 ATRs ) 57.2735
Upper Bollinger Band 63.4065
Lower Bollinger Band 55.6355
Percent B (%b) 0.95
BandWidth 13.0559
MACD Line 1.1210
MACD Signal Line 0.9342
MACD Histogram 0.1868
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 63.0000
Resistance 3 (R3) 63.0000 63.0000 63.0000
Resistance 2 (R2) 63.0000 63.0000 63.0000 63.0000
Resistance 1 (R1) 63.0000 63.0000 63.0000 63.0000 63.0000
Pivot Point 63.0000 63.0000 63.0000 63.0000 63.0000
Support 1 (S1) 63.0000 63.0000 63.0000 63.0000 63.0000
Support 2 (S2) 63.0000 63.0000 63.0000 63.0000
Support 3 (S3) 63.0000 63.0000 63.0000
Support 4 (S4) 63.0000